Stockreport

Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]

Zentalis Pharmaceuticals, Inc. - common stock  (ZNTL) 
PDF ZNTL's valuation has plummeted over 85% since late 2023, driven by clinical setbacks, a partial FDA hold, and market skepticism despite a strong cash position into 2027 [Read more]